Nektar Therapeutics Showcases Innovative Pipeline at Key Healthcare Conferences in March 2026

Nektar Therapeutics Engages in Key Industry Conferences to Highlight Pipeline Advances

Nektar Therapeutics, a clinical-stage biotechnology company based in San Francisco, announces its participation in two major healthcare conferences scheduled for early March 2026. The company aims to leverage these events to showcase its innovative pipeline of therapies targeting autoimmune and chronic inflammatory diseases. This proactive engagement with industry experts and stakeholders signifies Nektar's commitment to advancing its clinical programs and raising awareness about its promising candidates.

At the TD Cowen 46th Annual Health Care Conference in Boston, which takes place from March 2-4, Nektar management is set to present on March 4 at 9:10 a.m. Eastern Time. The presentation will be accessible via a webcast, which will remain available for a month post-event, allowing for broader stakeholder access and engagement. Following this, Nektar will participate in the 2026 Jefferies Biotech on the Beach Summit in Miami from March 9-11, providing additional opportunities for direct interaction with investors and industry peers through one-on-one meetings. Such initiatives not only bolster Nektar's visibility but also serve as platforms to discuss advancements in its clinical trials and the strategic direction of its therapies.

Nektar’s lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is currently undergoing multiple Phase 2 clinical trials targeting conditions like atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus. The company is equally engaged in the development of several other candidates, including NKTR-0165 and NKTR-0166, which target inflammation, as well as NKTR-422, a modified hematopoietic colony-stimulating factor. In addition, Nektar’s collaboration on NKTR-255, an investigational IL-15 receptor agonist aimed at enhancing immune responses against cancer, underscores the company’s dedication to broadening its therapeutic impact in oncology.

As Nektar Therapeutics prepares for these pivotal events, stakeholders can find further information about the company's initiatives and developments by visiting Nektar's website or following its updates on LinkedIn. The participation in these conferences reflects Nektar’s strategic approach towards fostering collaborations and attracting investment, imperative for the advancement of its clinical programs in a competitive biopharmaceutical environment.